4. Discussion 
PPH, intraoperative bleeding
POSTPARTUM BLEEDING, INTRAOPERATIVE BLEEDING, ADVERSE EFFECTS
In the current study, we aimed to determine the effects of the timing of standard-dose oxytocin administration (which we routinely apply during cesarean sections in our clinic) on the amount of intrapartum and postpartum bleeding. Therefore, we administered oxytocin at two different times: before and after placenta removal. The main finding was that there was less intraoperative bleeding and less decrease in postoperative HB and HTC levels with oxytocin administration before placenta removal.Oxytocin is still the drug of choice for the prevention and treatment of PPH. According to WHO recommendations, oxytocin (10 IU, IM, or IV) is the recommended uterotonic agent for the prevention of PPH in all deliveries in all settings [There are many studies in the literature on the dose of oxytocin administration [Ahmadi [Mangla et al. [Takmaz et al. [Cecilia et al. [Torloni et al. [In a study by Tharwat et al. [There is a need for additional, well conducted, and well reported, trials on the timing of prophylactic oxytocin in women giving birth by CS, to increase the overall certainty of the evidence on this important clinical question. Ideally, future RCTs should be placebo-controlled and double-blinded, involve other obstetric populations (women with previous CS and those at high risk for PPH), as well as other types of CS (in the 1st and 2nd stages of spontaneous and induced labor previously exposed to oxytocin), and measure all PPH prevention core results, including adverse effects and women’s views.The following study limitations were identified: (1) it was a single-center study; (2) a group of spontaneous vaginal deliveries was not formed; (3) a group with emergency cesarean sections other than elective cesarean sections was not formed; and (4) only cesarean sections at 38–40 weeks of gestation were evaluated.